A new peer review paper affirms that CooperVision MiSight 1 day contact lenses provide myopia control for nearly all children.†1 In the longest-running soft contact lens study among children, 90% of myopic eyes responded† to MiSight 1 day wear with a proportional treatment effect, meaning that younger and faster-progressing children receive the maximum benefit.1 Evidence also indicated a sustained slowing of eye growth with no loss of effectiveness over time.‡1
The findings were published in Optometry and Vision Science, the peer review journal of the American Academy of Optometry. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial (Chamberlain P, et al.) is now available via Open Access. The peer-reviewed sixyear paper complements additional CooperVision research demonstrating that the lens slows the rate of myopia progression by half, at all observed ages.†Åò1,2 The data also support that it’s never too late to start treatment, as the lens halves myopia progression in older children as well.||2
“Myopia is a disease that progresses over many years, so demonstrating sustained efficacy is critical,”‡1 said Paul Chamberlain, BSc (Hons), MCOptom, the study’s principal investigator and CooperVision Director of Research Programs. “Eye care professionals can prescribe MiSight 1 day with confidence knowing that the majority of children respond to treatment which lasts.”
The MiSight 1 day study is the world’s longest running soft contact lens clinical trial for myopia management. This new paper joins a growing body of peer-reviewed research stemming from the CooperVision MiSight 1 day study including Ocular Health of Children Wearing Daily Disposable Contact Lenses Over a 6-year Period (Woods J, et al) and Axial Length Targets for Myopia Control (Chamberlain P, et al), as well as the recent Garland W. Clay Award winner, A 3-year Randomised Clinical Trial of MiSight Lenses for Myopia Control (Chamberlain P, et al).
- Chamberlain P et al. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci 2022 In Press.
- Arumugam B, Bradley A, Hammond D, Chamberlain P. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2333.
† 90% of myopic eyes respond to MiSight 1 day treatment; ages 11-15 at start of wear, n=90.
‡ While eyes are still growing; children fit ages eight to 12 and followed for six-years. n=40
- Using measured and modelled data, pooled across ages (eight to 17), MiSight 1 day slowed myopia progression by an average of approximately 50%.
|| Children ages eight to 15 when starting MiSight 1 day treatment experienced a slowing of myopia progression.